Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Abstract Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi). Exposure to conventional platinum-based the...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2021-08-01
|
| Edice: | Hereditary Cancer in Clinical Practice |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s13053-021-00193-y |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|